| HOME >> MEDICINE >> TECHNOLOGY |
$
794$
769$ 1,608$ 1,479NEUPOGEN®- U.S.
268230507450Neulasta®- ROW
221246446472NEUPOGEN®- ROW
6481130157Enbrel®- U.S.
9918941,8691,715Enbrel®- Canada
6762127116Aranesp®- U.S.
215241417491Aranesp®- ROW
321344637674EPOGEN®- U.S.
5255439711,078Sensipar®- U.S.
150124290240Mimpara®- ROW
8275161146Vectibix®- U.S.
31316261Vectibix®- ROW
595011895Nplate®- U.S.
504010477Nplate®- ROW
36357263XGEVA®- U.S.
15673295115XGEVA®- ROW
23-37-Prolia®- U.S.
753012947Prolia®- ROW
45147924Other - ROW
27114211Total product sales
$ 4,200$ 3,893$ 8,101$ 7,511U.S.
$ 3,255$ 2,975$ 6,252$ 5,753ROW
9459181,8491,758Total product sales
$ 4,200$ 3,893$ 8,101$ 7,511 Amgen Inc.Condensed Consolidated Balance Sheets - GAAP (In millions)(Unaudited)June 30, December 31, 20122011AssetsCurrent assets:Cash, cash equivalents and marketable securities
$
22,475$
20,641Trade receivables, net
2,7082,896Inventories
2,5922,484Other current assets
1,7871,572Total current assets
29,56227,593Property, plant and equipment, net
5,4375,420Intangible assets, net
3,4702,584Goodwill12,42811,750Other assets
1,3291,524Total assets
$
52,226$
48,871Liab
'/>"/>
| SOURCE Amgen Copyright©2012 PR Newswire. All rights reserved |